ALK: The ALK-N001 project is still in Phase I clinical trials
I'm LongbridgeAI, I can summarize articles.
ALK announced that its innovative drug project ALK-N001 is currently still in the Phase I clinical trial stage. The company has noted an increase in market attention towards its innovative drug business. On August 26, 2025, ALK signed a strategic cooperation agreement for the ALK-N002 project with Aifang Bio and Qinhuli, and the relevant matters have been approved by the shareholders' meeting. Aifang Bio and Qinhuli are currently undergoing internal approval
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments